Results 41 to 50 of about 39,758 (253)

The Use of Prasugrel and Ticagrelor in Pipeline Flow Diversion [PDF]

, 2018
Background: Despite the routine clopidogrel/aspirin anti-platelet therapy, complications like thromboembolism, continue to be encountered with PED.
Atallah, MD, Elias, Bekelis, MD, Kimon, Chalouhi, MD, Nohra, Eller, MD, Gorge, Hasan, MD, David, Jabbour, Pascal, MD, Rosenwasser, MD, MBA, FACS, FAHA MD, Robert H., Saad, MD, Hassan, Stidd, MD, David, Tjoumakaris, MD, Stavropoula   +9 more
core   +2 more sources

Genetic polymorphisms and drug interactions leading to clopidogrel resistance: why the Asian population requires special attention [PDF]

, 2013
Ischemic heart disease and stroke are the two leading causes of death worldwide. Antiplatelet therapy plays the most significant role in the management of these cardiovascular and cerebrovascular occlusive events to prevent recurrent ischemic attack ...
Basri, Hamidon, Hasan, Md. Shariful, Lim, Poh Hin, Stanslas, Johnson   +3 more
core   +1 more source

Transcatheter interatrial shunt device for the treatment of heart failure with preserved ejection fraction (REDUCE LAP-HF I [Reduce Elevated Left Atrial Pressure in Patients With Heart Failure]): A phase 2, randomized, sham-controlled trial [PDF]

, 2018
Background -In non-randomized, open-label studies, a transcatheter interatrial shunt device (IASD, Corvia Medical) was associated with lower pulmonary capillary wedge pressure (PCWP), less symptoms, and greater quality of life and exercise capacity in ...
Basuray, Anupam, Burkhoff, Daniel, Fail, Peter S., Feldman, Ted, Forde-McLean, Rhondalyn, Hummel, Scott L., Kahwash, Rami, Kaye, David M., Lilly, Scott, Litwin, Sheldon, Massaro, Joseph M., Mauri, Laura, Nielsen, Christopher D., Penicka, Martin, Petrie, Mark C., Ricciardi, Mark J., Shah, Sanjiv J., van der Harst, Pim   +17 more
core   +1 more source

Is there a role for oral triple therapy in patients with acute coronary syndromes without atrial fibrillation? [PDF]

, 2018
© 2018 Bentham Science PublishersBACKGROUND: Acute coronary syndrome (ACS) patients, despite treatment with dual antiplatelet therapy (DAPT), have up to 10% risk of recurrent major adverse cardiac events (MACE) in the short term.
Akhtar, Zaki, Farag, Mohamed, Gorog, Diana Adrienne, Spinthakis, Nikolaos   +3 more
core   +2 more sources

The Effect of Ticagrelor for Endovascular Intervention of Intracranial Aneurysm Patients with or without Clopidogrel Resistant: A Meta-Analysis

Brain Sciences, 2022
Endovascular interventional is an important treatment method for intracranial aneurysms. However, due to the risk of intracranial thrombosis, prophylactic use of antiplatelet drugs is generally required.
Pengfei Xia, Yimin Huang, Gang Chen
doaj   +1 more source

Anti-platelet therapy: ADP receptor antagonists. [PDF]

, 2011
The P2Y(12) receptor on platelets with which ADP interacts has an important role in promoting platelet function and thereby platelet involvement in both haemostasis and thrombosis.
Heptinstall, S, Wijeyeratne, YD
core   +2 more sources

Clopidogrel resistance: What's new?

Archives of Cardiovascular Diseases, 2010
The concept of clopidogrel resistance emerged several years ago. Since then, many studies have been performed to elucidate the mechanisms and potential clinical impact of this biological finding. These studies identified complex mechanisms, including drug-drug interactions, genetic polymorphisms and clinical factors, and showed consistently the ...
Cuisset, Thomas, Cayla, Guillaume, Silvain, Johanne   +2 more
openaire   +2 more sources

9-(4'-dimethylaminophenyl)-2,6,7-trihydroxy-xanthene-3-one is a potentially novel antiplatelet drug which antagonizes the effect of thromboxane A2 [PDF]

, 2018
Background: Currently, used oral antiplatelet drugs are both limited and associated with the risk of treatment failure/resistance. Research in this area is hence highly desired.
Applová, Lenka, Durić, Kemal, Karlíčková, Jana, Macáková, Kateřina, Mladĕnka, Přemysl, Muratović, Samija, Saso, Luciano, Veljović, Elma, Završnik, Davorka   +8 more
core   +1 more source

Advantages and limitations of clopidogrel response testing methods [PDF]

, 2012
nem
Njegomirović Srđana, Ostojić Miodrag, Prostran Milica, Todorović Zoran, Đukanović Nina   +4 more
core   +1 more source

Efficacy of cilostazol on platelet reactivity and cardiovascular outcomes in patients undergoing percutaneous coronary intervention: insights from a meta-analysis of randomised trials [PDF]

, 2014
Background: Cilostazol overcomes high on-treatment platelet reactivity (HTPR) and reduces adverse cardiovascular (CV) outcomes after percutaneous coronary intervention (PCI).
Bangalore, Sripal, Bhatt, Deepak L, Croce, Kevin, DiNicolantonio, James J, Feit, Frederick, Singh, Amita, Toklu, Bora   +6 more
core   +1 more source